AU2015271652B2 - Methods of treating neurodevelopmental diseases and disorders - Google Patents

Methods of treating neurodevelopmental diseases and disorders Download PDF

Info

Publication number
AU2015271652B2
AU2015271652B2 AU2015271652A AU2015271652A AU2015271652B2 AU 2015271652 B2 AU2015271652 B2 AU 2015271652B2 AU 2015271652 A AU2015271652 A AU 2015271652A AU 2015271652 A AU2015271652 A AU 2015271652A AU 2015271652 B2 AU2015271652 B2 AU 2015271652B2
Authority
AU
Australia
Prior art keywords
disorder
day
hda
royal jelly
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015271652A
Other languages
English (en)
Other versions
AU2015271652A1 (en
Inventor
Wah Chin BOON
Steve Cheung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wah Chin Boon
Original Assignee
Wah Chin Boon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014902173A external-priority patent/AU2014902173A0/en
Application filed by Wah Chin Boon filed Critical Wah Chin Boon
Publication of AU2015271652A1 publication Critical patent/AU2015271652A1/en
Assigned to WAH CHIN BOON reassignment WAH CHIN BOON Request for Assignment Assignors: DEAKIN UNIVERSITY, THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH
Application granted granted Critical
Publication of AU2015271652B2 publication Critical patent/AU2015271652B2/en
Priority to AU2021221914A priority Critical patent/AU2021221914A1/en
Priority to AU2025200041A priority patent/AU2025200041A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Insects & Arthropods (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2015271652A 2014-06-06 2015-06-05 Methods of treating neurodevelopmental diseases and disorders Active AU2015271652B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021221914A AU2021221914A1 (en) 2014-06-06 2021-08-27 Methods of treating neurodevelopmental diseases and disorders
AU2025200041A AU2025200041A1 (en) 2014-06-06 2025-01-03 Methods of treating neurodevelopmental diseases and disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014902173 2014-06-06
AU2014902173A AU2014902173A0 (en) 2014-06-06 Methods of treating neurodevelopmental diseases and disorders
PCT/AU2015/050310 WO2015184509A1 (en) 2014-06-06 2015-06-05 Methods of treating neurodevelopmental diseases and disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021221914A Division AU2021221914A1 (en) 2014-06-06 2021-08-27 Methods of treating neurodevelopmental diseases and disorders

Publications (2)

Publication Number Publication Date
AU2015271652A1 AU2015271652A1 (en) 2017-01-05
AU2015271652B2 true AU2015271652B2 (en) 2021-05-27

Family

ID=54765877

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015271652A Active AU2015271652B2 (en) 2014-06-06 2015-06-05 Methods of treating neurodevelopmental diseases and disorders
AU2021221914A Abandoned AU2021221914A1 (en) 2014-06-06 2021-08-27 Methods of treating neurodevelopmental diseases and disorders
AU2025200041A Pending AU2025200041A1 (en) 2014-06-06 2025-01-03 Methods of treating neurodevelopmental diseases and disorders

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021221914A Abandoned AU2021221914A1 (en) 2014-06-06 2021-08-27 Methods of treating neurodevelopmental diseases and disorders
AU2025200041A Pending AU2025200041A1 (en) 2014-06-06 2025-01-03 Methods of treating neurodevelopmental diseases and disorders

Country Status (12)

Country Link
US (3) US9925163B2 (enExample)
EP (1) EP3151824B1 (enExample)
JP (2) JP6598262B2 (enExample)
KR (1) KR102496390B1 (enExample)
CN (1) CN106659704B (enExample)
AU (3) AU2015271652B2 (enExample)
BR (1) BR112016028653A2 (enExample)
CA (1) CA2951288C (enExample)
ES (1) ES3014042T3 (enExample)
MX (1) MX377588B (enExample)
NZ (1) NZ727412A (enExample)
WO (1) WO2015184509A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016028653A2 (pt) 2014-06-06 2018-07-10 Deakin University métodos de tratamento de doenças e distúrbios neurodesenvolvimentais
AU2016364670B2 (en) * 2015-12-04 2022-08-04 Wah Chin Boon Methods of treating or alleviating mental disorders and associated symptoms
CN116570582A (zh) * 2023-05-19 2023-08-11 中国药科大学 10-羟基癸烯酸在制备重度抑郁治疗药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0967252A (ja) * 1995-09-05 1997-03-11 Zenkoku Royal Jelly Kosei Torihiki Kiyougikai ローヤルゼリーに含まれるトランス−１０−ヒドロキシ−デセン酸を有効成分とするアンジオテンシン転換酵素阻害剤及びインスリン様作用剤
WO2007130581A2 (en) * 2006-05-04 2007-11-15 Hardwicke Susan B Compositions and methods for psychiatric conditions and cognition enhancement
EP2311472A1 (en) * 2008-06-17 2011-04-20 Japan Royal Jelly Co., Ltd. Cognitive disorder-ameliorating agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1025185A (en) 1911-03-23 1912-05-07 William J Gruss Regrinder.
WO2009038110A1 (ja) 2007-09-19 2009-03-26 Nagoya Industrial Science Research Institute 神経栄養因子様作用剤
LT2667715T (lt) * 2011-01-27 2017-11-10 Neuren Pharmaceuticals Limited Autizmo spektro susirgimų gydymas, naudojant glicil-l-2-metilprolil-l-glutamo rūgštį
US10052319B2 (en) * 2012-04-26 2018-08-21 Sumitomo Dainippon Pharma Co., Ltd. Medicament for treating mental and behavioural disorders
RU2602810C2 (ru) * 2012-04-27 2016-11-20 Ниппон Дзоки Фармасьютикал Ко., Лтд. Производное транс-2-деценовой кислоты и содержащее его лекарственное средство
CN103816307B (zh) 2014-03-12 2016-09-14 张国显 神经生长再造丸及其制备方法
BR112016028653A2 (pt) 2014-06-06 2018-07-10 Deakin University métodos de tratamento de doenças e distúrbios neurodesenvolvimentais
AU2016364670B2 (en) 2015-12-04 2022-08-04 Wah Chin Boon Methods of treating or alleviating mental disorders and associated symptoms

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0967252A (ja) * 1995-09-05 1997-03-11 Zenkoku Royal Jelly Kosei Torihiki Kiyougikai ローヤルゼリーに含まれるトランス−１０−ヒドロキシ−デセン酸を有効成分とするアンジオテンシン転換酵素阻害剤及びインスリン様作用剤
WO2007130581A2 (en) * 2006-05-04 2007-11-15 Hardwicke Susan B Compositions and methods for psychiatric conditions and cognition enhancement
EP2311472A1 (en) * 2008-06-17 2011-04-20 Japan Royal Jelly Co., Ltd. Cognitive disorder-ameliorating agent

Also Published As

Publication number Publication date
US10933043B2 (en) 2021-03-02
AU2021221914A1 (en) 2021-09-23
US20180214405A1 (en) 2018-08-02
EP3151824A1 (en) 2017-04-12
ES3014042T3 (en) 2025-04-16
US10251856B2 (en) 2019-04-09
MX377588B (es) 2025-03-10
JP2019214623A (ja) 2019-12-19
CA2951288A1 (en) 2015-12-10
BR112016028653A2 (pt) 2018-07-10
KR20170026457A (ko) 2017-03-08
CA2951288C (en) 2024-01-02
US20190314315A1 (en) 2019-10-17
NZ727412A (en) 2023-07-28
CN106659704A (zh) 2017-05-10
JP6598262B2 (ja) 2019-10-30
AU2015271652A1 (en) 2017-01-05
CN106659704B (zh) 2020-03-10
US9925163B2 (en) 2018-03-27
JP6994613B2 (ja) 2022-01-14
MX2016016118A (es) 2017-07-26
WO2015184509A1 (en) 2015-12-10
KR102496390B1 (ko) 2023-02-03
JP2017517574A (ja) 2017-06-29
US20170087110A1 (en) 2017-03-30
EP3151824A4 (en) 2017-12-20
AU2025200041A1 (en) 2025-01-23
EP3151824B1 (en) 2025-03-05
EP3151824C0 (en) 2025-03-05

Similar Documents

Publication Publication Date Title
AU2025200041A1 (en) Methods of treating neurodevelopmental diseases and disorders
US20220117925A1 (en) Methods of treating or alleviating mental disorders and associated symptoms
TW201605443A (zh) 治療ｘ染色體脆折症及相關病症的方法
JP2019511495A (ja) ＧＳＫ３β阻害薬チデグルシブによるＣＤＫＬ５障害の治療
US6432992B1 (en) Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy
US12036237B2 (en) Bromide source for use in treating autism spectral disorder
CA2940573A1 (en) Xanthone-rich plant extracts or compounds therefrom for modulating diseases of the central nervous system and related disorders
EP4205734A1 (en) Application of ?-asarone in preparation of medicine for preventing or treating hemorrhagic stroke
JP2023544429A (ja) 運動ニューロン疾患及び神経筋接合部障害の処置のためのｎ－（３－（４－（３－（ジイソブチルアミノ）プロピル）ピペラジン－１－イル）プロピル）－１ｈ－ベンゾ［ｄ］イミダゾール－２－アミン硫酸塩及びそれらの溶媒和物の使用
HK1232805A1 (en) Methods of treating neurodevelopmental diseases and disorders
RU2814327C1 (ru) ПРИМЕНЕНИЕ СУЛЬФАТНЫХ СОЛЕЙ N-(3-(4-(3-(ДИИЗОБУТИЛАМИНО)ПРОПИЛ)ПИПЕРАЗИН-1-ИЛ)ПРОПИЛ)-1Н-БЕНЗО[d]ИМИДАЗОЛ-2-АМИНА И ИХ СОЛЬВАТОВ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ДВИГАТЕЛЬНЫХ НЕЙРОНОВ И НАРУШЕНИЙ НЕРВНО-МЫШЕЧНЫХ СОЕДИНЕНИЙ
WO2025162745A1 (en) Treatment of gm1 gangliosidosis
CN105456257A (zh) 胺类化合物的光学异构体治疗焦虑障碍的医药用途
CN113453761A (zh) 皮特-霍普金斯综合征的治疗
CN113423406A (zh) 用于治疗皮特-霍普金斯综合征的米诺环素
CN111225667A (zh) 一种1,2,3,6,7-五甲氧基二苯吡酮在制备防治海马神经元相关疾病药物的应用

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: WAH CHIN BOON

Free format text: FORMER APPLICANT(S): THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH; DEAKIN UNIVERSITY

FGA Letters patent sealed or granted (standard patent)